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Abstract 
Given rising costs and declining R&D productivity, the pharmaceutical industry needs information 
systems and processes that contribute to business efficiency and cost reduction without compromising 
fundamental quality and safety principles. This study investigated quality information systems in the 
pharmaceutical industry and the relationship between the industry and its regulators. The data 
demonstrated a risk-based approach to information management and a quality-by-design philosophy in 
the industry, aiming to satisfy the needs of product regulators, optimise manufacturing process 
efficiencies, and give patients reliably consistent medicines and devices. The data also revealed a 
problematic perception of regulatory oversight, with highly significant correlations between level of 
regulator contact and ‘difficulty’ with regulators (r=0.92) and between difficulty with regulators and 
delays in IT implementations (r=0.87).We propose that emerging trends in standards-based 
interoperability offer a new paradigm for the industry and its regulators. 
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1.0 Introduction 
The pharmaceutical manufacturing industry is heavily regulated and quality driven. 
This requires the gathering of considerable amounts of data and information to prove 
product quality. The secondary use of this data also supports continuous process 
improvement initiatives, dealing with process optimisation, reliability and efficiency 
aspects of the manufacturing environment. Data integrity, security and traceability are 
of paramount importance to guarantee product safety. The principal regulatory 
authorities are the US Food and Drugs Administration (FDA), the European 
Medicines Agency (EMA), the UK Medicines and Healthcare products Regulatory 
Agency (MHRA) and the Japan Pharmaceutical Manufacturers Association (JPMA). 
Joint projects involving the pharmaceutical industry and all its global regulators are 
coordinated through the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH). 
 
This paper reports a project that examined pharmaceutical product quality information 
to identify and assess significant issues for regulators, quality compliance 
professionals and process improvement experts. 
 
The overall aim was to discover whether the pharmaceutical industry is using best 
practice to manage information and whether the regulatory bodies are having a 
positive or negative effect on information management. 
 
1.1 Product quality information 
Registration of a new product with the regulators includes defining the set of critical 
quality information that is declared to be imperative to the outcome of the product. 
This is derived from the stages of drug development, validation, and transfer to 
production processes. For example, the whole process of tablet production can 
include: mixing the active pharmaceutical ingredients with excipients such as binders, 
filler and colouring material, forming the mixture into granules and finally 
compression into tablet form (Cole, 1998). Each item added to the mixture must be 
measured and inspected, the vessel itself must be at a specified temperature and also 
inspected, the weight of the final product must be noted and many other more 
scientific measurements as well. 
 
Product quality information is information identified from critical stages in the 
production process of a product. Such information as the pressure a tablet breaks 
during the compression stage, temperature of a room, weight of a device, signature of 
completion, and quantities. This data is stored in batch records, compliance records, 
laboratory data, manufacturing data, training records, calibration tracking records, and 
audit trails. General automated procedures along the production line will collate and 
import data into a database. This information is usually printed out, signed, and 
counter signed and attached to a batch of product, to provide traceability for 
regulatory bodies. Other bespoke software will manage documentation, quality, 
product lifecycle, audit, training, bill of materials, and submissions management.  
 
Pharmaceutical companies strive to meet stringent regulations to deliver the highest 
quality possible. Failure in delivering a satisfactory product can result in prosecution 
and product recalls. The substantial expense of bringing a new product to market is 
not recovered when a product is withdrawn from sale.   Product recalls can result from 
patient complaints, regulatory observations or a manufacturer identified problem. 
 
 
1.2 Regulatory initiatives 
Regulators set the information standards for pharmaceutical production and have 
emphasised the need to ensure that computer systems that run throughout the process 
of drug production are as safe and secure as the production process and materials 
themselves. 
 
Part 11 of the FDA’s Code of Federal Regulations (CFR) requires pharmaceutical 
manufacturers to provide controls utilising audits, validation systems, and 
documentation. These control systems are part of operations and product 
development. Part 11 also highlights the need to have procedural controls such as 
training, Standard Operating Procedures (SOP), and administration to support this 
code. Part 820 further presents the need for a robust quality system in the manufacture 
of pharmaceuticals. 
 
The Process Analytical Technology (PAT) initiative is a system for designing, 
analysing, and controlling manufacturing through measurements primarily during 
processes. Its ultimate goal is to ensure the product manufactured is of sufficient 
quality (FDA, 2011). The key objectives of PAT are to reduce the production cycle 
times by using measurements and controls, preventing rejects, scrap, and re-
processing. Another key objective is to increase automation to improve operator 
safety and reduce human error whilst facilitating continuous processing to improve 
efficiency and manage variability. The tools that assist in this movement are 
multivariate data acquisition and analysis tools, process analysers or process 
analytical chemistry tools, along with process and endpoint monitoring and control 
tools. All of this endeavours to achieve continuous improvement and improve existing 
manufacturing and associated regulatory practices that do not adequately support or 
facilitate innovation and continuous improvement. The sole focus of the PAT is to 
understand and control the manufacturing process. 
 
Additionally there are site inspections; the MHRA, for example, has three types of 
inspection. The first type scheduled inspections that UK Market Authorisation 
Holders (MAHs) undergo on a periodic basis. The second is ‘For Cause’ national 
inspections (MHRA, 2011).  These are ad hoc inspections that are triggered as a result 
of, for example, safety issues, suspected violations of legislation relating to 
monitoring of the safety of medicines, referrals by other EU Member States. Finally 
the last is the Committee for Medicinal Product for Human Use (CHMP) requested 
inspection (MHRA, 2011). The CHMP may request inspections of MAHs in 
association with specific centrally authorised products. 
 
1.3 Financial pressures 
Whereas the overall research and development cost of bringing a new drug to market 
has increased from around US$800m in 2003 to something in the order of US$1.5bn 
in 2009, productivity has declined disproportionately (Collier, 2009). This context 
demonstrates the pharmaceutical industry’s need for information systems and 
processes that contribute to business efficiency and cost reduction without 
compromising fundamental quality and safety principles. 
 
1.4 Methods 
The methodology chosen for this study comprised two parts. A semi-structured 
interview was conducted with a Lean Six Sigma process improvement specialist in a 
major UK pharmaceutical manufacturer, with qualitative analysis based on a hybrid of 
Soft Systems Methodology (SSM) (Checkland, 2006) and Effective Technology and 
Human Implementation of Computer Supported Systems (ETHICS) (Mumford, 
1996). The quantitative element used a survey. This paper reports primarily the 
quantitative findings, with some illustrative explanatory data from the qualitative 
work included in the Discussion section. 
 
The survey was distributed via the Human Resources department of a UK-based 
pharmaceutical manufacturer. As this study is primarily exploratory, a sample size of 
30 was judged to be adequate, with interpretive emphasis given to the qualitative 
interview data. The survey primarily used standardised closed-ended questions to 
allow stable data to analyse. This simple survey was to substantiate and clarify 
qualitative findings from the interviews. Quantitative survey data was analysed using 
SPSS and Microsoft Excel, with Likert scaled items coded to numeric values. 
Confidence intervals (CIs) and Pearson correlations were calculated for some 
responses and interrelationships. 
 
Survey questions 1-4 were demographic items, covering gender, employment status, 
age group and job role. The substantive questions are listed below:
• Q.5: How many times have you been in direct or indirect contact with regulators such as 
the FDA or MHRA? 
• Q.6: How many projects have you been a part of where you had difficulty in meeting 
regulatory requirements? 
• Q.7: Has your company adopted the PAT initiative? (Process Analytical Technology)
• Q.8: How important do you feel regulator involvement is in projects you have
of? 
• Q.9: If IMPORTANT, please explain why?
• Q.10: Have you or your manager postponed implementing IT solutions because you feel 
you may not comply with regulations?
• Q11: If YES, please explain why?
• Q.12: I fully understand regulations affecting
• Q.13: If No, please explain why?
• Q.14: Does the company you work for support and encourage IT innovation?
• Q.15: How many projects roughly in the past year have you been involved in where 
information technology was a key componen
 
2.0 Results and Analysis
Thirty survey responses were received. 
staff, mostly in full-time employment. 
respondents and Figure 2 shows the range of job roles represented
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The sample comprised 27 male and 3 female 
Figure 1 shows the age distribution 
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2.1 Q.5 Contact with Regulators vs. Q.6 Difficulty with Regulators
The Pearson correlation between the difficulty respondents had with regulators and 
the amount of contact a respondent had with regulators was found to be 
substantial and statistically 
professionals spend the most time interacting with regulators at a rate of 21.25 times 
in their current working career. The survey also indicates they 
difficulty in meeting requirements.
can be detail orientated and essentially the main aim is to comply with regulators and 
make sure the product or process is safe and efficient. On average
technologists have had the most difficulty in meeting regulatory requirements
could be due to the fact they are not as knowledgeable as quality professionals in 
regulatory requirements. 
relationship or the business infrastructure doesn’t support this interaction. 
correlation is high at .92 it is fair to state that the difficulty respondents had increased 
when contact with regulators, direct or indirect, occurred. This may suggest that there 
are weaknesses with the communication between the two parties and therefore may 
need further improvement as to accomplish a sophisticated communication system
Another area which this highlights is the lack of or poor connection between business 
and IS strategy. Without a close relationship with the two strategies, gaps in 
communication and focu
company. 
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significant with r(28) = .92, p < .01. On average
have high rates of 
 This could be due to the fact in quality roles, tasks 
This could also suggest that IT and Quality have a poor 
s can allow conflicting ways of working throughout a 
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 2.2 Q.7 - Has your company adopted the PAT initiative? 
50% of respondents are aware their company has adopted the PAT initiative from the 
FDA. This suggests that companies are taking this process analytical technology 
seriously and or see a serious benefit it can make to the business. The 26% of 
respondents who ‘Don’t know’ may be as a result of their area of work and they may 
not be required to know about this FDA initiative 
 
2.3 Q.8 - How important do you feel regulator involvement is in projects you 
have been a part of? 
The 95% CI was 3.49 – 4.24 (on a Likert scale where ‘Definitely unimportant’ was 
coded as 1 and ‘Definitely important’ was coded as 5). This suggests a perception of 
the regulator as a necessary stakeholder rather than a negative interference. Another 
area of interest is the two extremes of the Likert scale. None of the respondents chose 
“Don’t Know”, this indicates a strong feeling or that it was a simple straight forward 
question. On the other side of the scale only one person stated that regulator 
involvement was definitely unimportant; looking in more depth the respondent’s role 
was of a process improvement type. Process improvement can be a difficult role when 
detailed systems engineering tasks sometimes create friction with regulators. 
 
2.4 Q.8 Importance of Regulators vs. Q.4 Job Role 
Table 1 demonstrates the relationship between how the respondents perceive regulator 
importance within projects and their job role.  As the table shows, the majority of 
respondents opted for ‘mostly important’. The purpose of this cross tabulation is to 
identify if job role relates to what they feel about regulators. 
 
The most interesting result came from the Process Improvement staff, the weight of 
their answers being in the unimportant category. This may be due to the difficult tasks 
of re-engineering processes and encompassing strict regulatory rules whilst trying to 
improve the system. 
 
 
 
Job 
Definitely 
Unimportant 
Mostly 
Unimportant 
Neutral 
Mostly 
Important 
Definitely 
Important 
Don't 
Know 
Quality 0 0 2 3 2 0 
Info 
Management 
0 0 1 4 1 0 
Regulatory 0 0 0 0 1 0 
Information 
Technology 
0 0 1 4 2 0 
Process 
Improvement 
1 1 0 1 0 0 
Other 0 1 1 2 1 0 
Table 1. Importance of Regulators vs. Job Role. 
 
2.5 Q.9 - If IMPORTANT, please explain why? 
This question leads from Q.8 and the overall response was that regulators are there to 
help and ensure products are produced in a safe manner and do what they say they are 
supposed to do, thus providing substantiated evidence. Another comment states “It is 
useful to have such a well-developed governing body but at the end of the day we 
ensure product safety and are always proactive in achieving the best.” This highlights 
the appreciation of regulators but the industry governs itself and utilises the regulators 
as a last resort. Two negative responses occurred stating “It is important but 
sometimes I feel there are too many rules and regulations” and “It can be a hindrance 
at times.” These responses may be the result of a negative experience in the past and 
therefore appreciate the importance but believe there could be room for improvement. 
 
2.6 Q.10 Postpone Implementing IT vs. Q6 Difficulty with Regulators 
The Pearson correlation between the difficulty respondents had with regulators and 
the amount of respondents who felt they had to postpone IT projects due to regulatory  
compliance was found to be substantial and statistically significant with r(28) = .87, p 
< .01. Although there could be many other factors which may defer respondents 
implementing IT, this Pearson correlation demonstrates one factor which suggests 
regulatory involvement in IT projects has stopped innovation. As the correlation is 
high at .87 it is fair to state that there is a significant issue relating the difficulty a 
respondent had and a resulting postponement of IT projects. It is important to state 
that the postponement of IT projects can have many reasons, however the high 
correlation suggest there is an issue with how regulators are impacting the adoption of 
new technologies and systems. 
 
2.7 Q.11 - If YES, please explain why? 
This question leads from Q.10 and the purpose was to find out in more detail why the 
respondent felt they put off implementing IT. The major point identified was that 
validation was sometimes difficult and complex. One interesting comment stating 
“CFR part 11 is a pain.” This demonstrates that regulatory issues were impacting IT 
projects and predominantly at the validation stage. 
 
2.8 Q.12 - I fully understand regulations affecting me in my day to day work 
The response to this question highlights the majority of respondents believe that they 
fully understand regulations. Whether their belief is justified could be a possible 
avenue of further enquiry. However 83% gives a good indication that they are 
comfortable with regulations and that they perceive them to be understandable.  
 
2.9 Q.13 - If No, please explain why? 
This question leads from Q12 and tries to identify the knowledge of regulations in a 
respondent’s daily task. The main point presented by the respondents was that it all 
seems complex. One respondent said “I get informed of big new regulations. The rest 
is just built into your work from the beginning so you’re not really aware all the 
time.” This suggests that significant initiatives such as PAT are presented effectively, 
however the basic tasks that come from “cGMP” (current Good Manufacturing 
Practice) are built into the work and therefore do not take much precedence in the 
respondents mind. From a consultant’s perspective the respondent suggests a way 
they handle regulations. “I take each project as it comes and rely on the company 
knowing the rules. Close consultation with validation, quality, and the head of the 
department assist in my understanding. Most of my knowledge is old from when I 
worked in Pharmaceuticals.” 
 
 
 
2.10 Q.14 - Does the company you work for supp
innovation? 
76% of respondents agree
stated they did not know, which suggests they are either not involved with IT as much 
as the others or that their company does
 
2.11 Q.15 - How many projects roughly in the past year have you been 
involved in where information technology was a key component?
 
63% stated they were involved with 
minority of staff who are involved with very high numbers of projects each year.
confirms that IT projects are viewed as routine and are integral to pharmaceutical 
operations. 
 
3.0 Discussion 
It might be expected that regulation is 
pharmaceutical manufacturing industry and its technology through strict rules and 
compliance audits. The qualitative part of this 
had a formative influence on
the way pharmaceuticals work. 
point. The first quotation is recalling the state of the industry in the 1970s
“Although I was subsequently in a responsible position in this manufa
department, I don’t recall seeing
there ever was one. 
6
ort and encourage IT 
d that IT innovation is encouraged. 16% of respondents 
 not demonstrate IT innovation effectively.
 
five IT projects or less, while there is also a 
the primary driving force 
study indicated that although 
 technology adoption it is no longer the principal factor in
Relevant extracts from an interview illustrate this 
 the ‘Systems Requirements Specification’, if 
Regulation of computer systems was limited and relied on 
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the expertise of a few individuals. I doubt if there was a formal validation 
report; whether the computer equipment and its use was verified and properly 
controlled... The regulators recognised the importance of quality critical 
information management during the processing of this product, but they put 
more emphasis on the quality of the end product as determined by various 
laboratory tests.” 
This can be contrasted with a subsequent quotation about progress since the 1990s: 
“There was a growing emphasis on process reliability and waste reduction in 
our Company in an attempt to move towards ‘World Class’ standards... This 
was made up of a combination of “Lean Manufacturing” waste elimination 
and “Six Sigma” process reliability principles. We wanted to move from 
failure rates of about 99% (analogous to 200,000 wrong drug prescriptions 
every year) to a six sigma level of 99.99966% (equivalent to 68 wrong 
prescriptions a year)... The regulatory bodies are now recognizing the mutual 
benefits of using data, information, knowledge and understanding of 
processes; to design and make consistently effective drug products... the 
Pharmaceutical Industry and the regulatory authorities are now growing even 
closer in achieving their mutual interests: cost reduction and consistently 
effective and reliable products. But this may come at the result of high initial 
costs. Some small pharmaceutical companies have limited resources to invest 
time and money into high quality regulatory compliance and may not be able 
to adopt the full principles of the PAT philosophy.” 
 
The survey data above has indicated that regulator involvement is now perceived to be 
associated with delays in information system implementations. The drive for process 
and quality improvement is seen to be vested in the interests of the pharmaceutical 
industry itself, not something that has to be externally imposed. 
 
The survey results suggest that fifty percent of the respondents are aware that their 
company is using the PAT initiative and even higher percentage state that their 
company is encouraging the use of IT in innovative ways. This indicates that, from 
the historical ‘that’ll do’ mentality mentioned in an interview, there has been a shift to 
companies actively pursuing a ‘best-in-class’ mentality. Although, as suggested, 
regulators are now working hard to assist in pharmaceutical manufacturing, the 
evidence from the survey results portrays a different view. The data shows that 
respondents who had more difficulty with regulators were then inclined to postpone 
IT projects. However it is imperative to mention that there could be many other 
factors that could impact IT projects. Although this is important to be aware of, the 
close relationship between these two variables suggests that regulators are not always 
perceived to be having the desired effect on innovation. This is an area that merits 
further investigation. 
 
As mentioned in the survey research the significance of the correlation is quite 
substantial and therefore the importance of the result must impact the project. With 
technology now driving regulation as discussed above, with the PAT initiative, the 
issue the findings present of the difficulty and postponement of IT projects shows that 
although regulators are embracing the importance of technology there are still areas 
most notably communication that need enhancement. This would greatly increase the 
implementation of IT in the pharmaceutical manufacturing industry. An increase of 
successful projects would also increase due to the reassurance that the IT systems 
would comply with regulations. This brings to the forefront the consideration that IT 
developers and staff must always incorporate the safety of the systems they 
implement. To conclude, the importance in technology is of great interest to this 
industry as it can increase production speed, reduce waste, and ultimately ensure 
quality. This realisation of IT supporting the manufacture of medicine and devices has 
now led to regulators having to become more aware of technology and enable IT 
innovation to work its way into moving the pharmaceutical industry into a 
sophisticated technology driven. 
 
Recent developments in information standards offer a new cooperative paradigm for 
the industry and its regulators. A good example is the “Identification of Medicinal 
Products” (IDMP) standard. This was a joint project run by ICH with HL7 (the global 
authority on standards for interoperability in healthcare IT), CDISC (the Clinical Data 
Interchange Standards Consortium, who provide file formats for regulated research), 
ISO (the international organization for standardization) and CEN (the European 
standards body). The aim of IDMP is to enable harmonized specification of medicinal 
products, and thereby standardize information flows between regulators, 
manufacturers, sponsors and other stakeholders. The same organizational 
collaboration has also produced information standards for adverse event reporting 
(“Individual Case Safety Report”, ICSR) and is also working on standards for clinical 
trial registration and results (CTRR). By working in a collaborative and aligned way, 
the regulators have had a constructive rather than constraining effect on industrial 
innovation and progress. 
 
We suggest this offers a good pattern for converging and aligning the business, 
technical and quality interests of the regulators and manufacturers. This kind of 
cooperative standards-based approach could be transferable to more general 
regulatory concerns and indeed to helping the industry move away from what is, 
anecdotally, a needlessly over-partitioned information environment to a more open 
culture of knowledge and information sharing. 
 
4.0 Conclusions 
 
This study has shown a problematic perception of pharmaceutical regulatory 
oversight, with highly significant correlations between level of regulator contact and 
‘difficulty’ with regulators (r=0.92) and between difficulty with regulators and delays 
in IT implementations (r=0.87).We propose that emerging trends in standards-based 
interoperability offer a new paradigm for the industry and its regulators. 
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